Investigation Launched into Corcept Therapeutics: A Closer Look at Shareholder Rights and Securities Violations

Investigation into Corcept Therapeutics: Examining Shareholder Rights

The Schall Law Firm, an esteemed national firm specializing in shareholder rights, has initiated an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) over potential violations of securities laws that may have impacted investors. This development follows alarming news regarding Corcept's New Drug Application (NDA) for relacorilant, intended to treat hypertension linked to hypercortisolism.

Background of the Situation

On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) concerning its NDA for relacorilant. The letter indicated that, while the FDA recognized that Corcept's pivotal GRACE trial achieved its primary endpoint and corroborative data from the GRADIENT trial were presented, it insisted that additional evidence demonstrating the drug's effectiveness was required before rendering a favorable benefit-risk assessment.

Unfortunately for shareholders, the consequences of this announcement were severe, leading to a drastic decline in Corcept's stock price, which plummeted by over 50% following the revelation. For many investors, such a drop raises grave concerns about the accuracy and reliability of the company’s prior communications related to their product and the overall health of their investments.

Implications for Investors

The Schall Law Firm's investigation will delve deeply into whether Corcept Therapeutics made misleading statements regarding the development and approval processes concerning relacorilant. For shareholders who may have suffered financial losses as a result of these recent developments, participating in the investigation could help clarify their rights and potential recourse.

For those affected, the law firm urges them to step forward and share their experiences. This is a crucial step as investors have the right to voice their concerns and seek justice when they believe they have been misled.

In addition, Brian Schall, a principal at the firm, has extended an invitation for affected shareholders to reach out for a free consultation regarding their rights, emphasizing the firm’s commitment to representing investors globally and specializing in securities class action lawsuits.

How to Participate

Shareholders interested in participating in this investigation are encouraged to contact The Schall Law Firm directly. The firm is headquartered at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, and can be reached at (310) 301-3335 or via their website at www.schallfirm.com for more information. Confidential inquiries via email can also be made through [email protected]

As this situation develops, The Schall Law Firm remains dedicated to advocating for shareholders who entrust companies with their investments. Understanding the full scope of the situation surrounding Corcept Therapeutics will be integral to ensuring that investor rights are upheld and respected in the financial marketplace.

This might be regarded as attorney advertising in some jurisdictions as per relevant laws and ethical regulations. Investors are advised to stay informed and proactive in their engagement with shareholder rights matters, as the outcome of such investigations can have far-reaching implications for the companies involved and their respective investors.